Topics:

ASCO 2014 Hematology

ASCO 2014 Hematology

Cancer Network presents exclusive coverage of hematologic malignancies from the American Society of Clinical Oncology (ASCO) annual meeting. We'll bring you reports of the latest research, trials, and scientific advances that are changing the way cancers of the blood are managed and treated.

ASCO 2014 Hematology

Ruxolitinib was significantly better than the best available therapy in a phase III, open-label trial of patients with polycythemia vera who were resistant to or intolerant of hydroxyurea.

A phase II trial of the selective spleen tyrosine kinase (Syk) inhibitor GS-9973 showed substantial biologic activity in patients with chronic lymphocytic leukemia (CLL).

Ibrutinib substantially increased progression-free survival and overall survival over ofatumumab in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), according to the results of the RESONATE trial.

Treatment with lenalidomide and dexamethasone improved quality-of-life measures in multiple myeloma patients, according to a study presented at the 2014 ASCO Annual Meeting.

Continuous therapy produces drastically better progression-free survival and overall survival outcomes in patients with multiple myeloma. A novel endpoint involving time to second progression is an important tool in evaluating this type of treatment in the future.

As part of our coverage of the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, we discuss the pros and cons of follow-up imaging in lymphoma.

Subscribe to ASCO 2014 Hematology on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.